<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064697</url>
  </required_header>
  <id_info>
    <org_study_id>18PH192</org_study_id>
    <secondary_id>2019-001032-54</secondary_id>
    <nct_id>NCT04064697</nct_id>
  </id_info>
  <brief_title>Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy</brief_title>
  <acronym>CYTOVEDO</acronym>
  <official_title>Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy. CYTOVEDO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative Colitis (UC) is an inflammatory bowel disease that can require the use of anti-TNF
      alpha therapy. When anti-TNF alpha failed to obtain a clinical response, the use of a new
      anti-integrin therapy, vedolizumab, can be proposed. The efficacy of vedolizumab has been
      assessed in a phase 3 study (GEMINI I), with response rates of 41.1% with vedolizumab vs
      25.5% with placebo.

      CytoMegaloVirus (CMV) reactivation has been associated with resistance to steroid and to
      several lines of immunosuppressive therapy. Antiviral therapy was proven to decrease the
      tissue viral load and to restore the response to immunosuppressive therapies (up to 80% in
      small group of patients). A recent meta-analysis supports the use of valganciclovir in case
      of CytoMegaloVirus (CMV) reactivation in active Ulcerative Colitis (UC).

      Moreover, a study showed that the risk of CMV reactivation seems to be more important with
      vedolizumab than with anti TNF, and the risk of colectomy is higher in case of
      CytoMegaloVirus (CMV) reactivation (p&lt;0.05).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is in Ulcerative Colitis (UC) patients with tissue
      CytoMegaloVirus (CMV) reactivation ; not responding to anti-TNF or without anti-TNF ; a
      treatment with valganciclovir, added to vedolizumab, could improve the clinical response.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Weeks 6</time_frame>
    <description>Percentage of patients in clinical response. the clinical response is defined by the decrease in the total Mayo Score compared to the inclusion of at least 3 points and at least 30% with a decrease in the score of bleeding (item 2 of the Mayo sub-score) from at least one point or sub-score of bleeding from 0 or 1 point with or without anti-CMV treatment. The Mayo score includes 3 items: stool frequency, presence of blood in the stool, and overall assessment of the disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Weeks 6</time_frame>
    <description>Percentage of patients in clinical remission defined by a total Mayo score &lt;3 with an endoscopic score &lt;2 and no clinical sub-score&gt; 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal healing</measure>
    <time_frame>Weeks 6</time_frame>
    <description>Percentage of patients in mucosal healing defined by endoscopic mayo score &lt;2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load CytoMegaloVirus (CMV)</measure>
    <time_frame>Weeks 6</time_frame>
    <description>Value of viral load CytoMegaloVirus (CMV) by qPCR on inflammatory tissue in IU / 100000 cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical remission</measure>
    <time_frame>Weeks 52</time_frame>
    <description>Percentage of patients in clinical remission defined by a total Mayo score &lt;3 with an endoscopic score &lt;2 and no clinical sub-score&gt; 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of colectomy</measure>
    <time_frame>Weeks 52</time_frame>
    <description>Percentage of patients who required colectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Weeks 52</time_frame>
    <description>Number and severity of adverse effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ulcerative Colitis, Unspecified</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will be treated by vedolizumab the standard of care alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be treated by vedolizumab the standard of care associated at valganciclovir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>antiviral therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with moderate to severe active Ulcerative Colitis (UC) defined by a Mayo score
             greater than 5

          -  Patient with an inflammatory outbreak of Ulcerative Colitis (UC) :

               -  without anti-TNF

               -  under anti-TNF (infliximab, adalimumab, golimumab) after induction (no primary
                  response) or clinical recurrence (secondary failure).

          -  Having rectosigmoidoscopy with an endoscopic Mayo score≥ 2 with 2 biopsies of the
             inflammatory tissue

          -  Presence of a CytoMegaloVirus (CMV) infection in the inflammatory tissue (viral load
             greater than 5 IU / 100000 cells by qPCR)

          -  Patient with a negative pre-treatment assessment including HIV, HBV, HCV, HCV
             serology, a negative quantiferon or a history of tuberculosis preventive treatment
             adapted by Rifinah or Rimifon

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient with severe acute colitis

          -  Patient treated by ciclosporin or Prograf

          -  Patient with Human Immunodeficiency Virus (HIV)+, hepatitis B, hepatitis C,
             tuberculosis

          -  Clostridium difficile infection.

          -  CytoMegaloVirus (CMV) positive viremia

          -  Patient with intolerance or contraindications to current therapy

          -  Pregnant or starts breastfeeding

          -  Patient who received a live vaccine in the month preceding the study

          -  Patients with severe renal insufficiency defined by creatinine clearance &lt;30ml/minute,
             or hemodialysed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline VEYRARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline VEYRARD, MD</last_name>
    <phone>(0)477828619</phone>
    <phone_ext>+33</phone_ext>
    <email>pauline.veyrard@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie PEURIERE, CRA</last_name>
    <phone>(0)477120826</phone>
    <phone_ext>+33</phone_ext>
    <email>Marie.Peuriere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Frédéric Heluwaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Pofelski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anthony Buisson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nicolas Mathieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stephane Nancey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Danion, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Flourie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Boschetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Romain Altwegg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucile Boivineau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jérôme Filippi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Hebuterne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Arab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Benard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Harry Sokol, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Pauline VEYRARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier ROBLIN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis (UC)</keyword>
  <keyword>CytoMegaloVirus (CMV)</keyword>
  <keyword>Vedolizumab</keyword>
  <keyword>Valganciclovir</keyword>
  <keyword>Anti-TNF</keyword>
  <keyword>Mayo score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

